Verastem, INC

Verastem Oncology announced positive updated safety and efficacy results from the RAMP 205 trial evaluating avutometinib plus defactinib in combination with chemotherapy for first-line metastatic pancreatic cancer.

Verastem, Inc. held its 2026 annual meeting where stockholders elected directors, approved equity and stock purchase plans, ratified auditor selection, and voted on executive compensation.

Verastem Oncology announced preliminary Q4 and full-year 2025 net product revenues for AVMAPKI FAKZYNJA CO-PACK, along with an extended cash runway into the first half of 2027 and key 2026 strategic priorities.

Verastem, Inc. announced significant progress in its oncology pipeline, including the commercial launch of AVMAPKI FAKZYNJA CO-PACK and promising clinical data for VS-7375, alongside robust Q3 2025 net product revenue of $11.2 million.

Verastem Oncology announced the discontinuation of its RAMP 203 clinical trial for advanced KRAS G12C-mutated NSCLC to prioritize other promising programs.

Verastem Oncology announced strategic leadership changes, including a new Chairman and President of Development, alongside the completion of patient enrollment for its RAMP 301 Phase 3 trial.

Verastem, Inc. reports increased revenue from its newly approved cancer drug AVMAPKI FAKZYNJA CO-PACK, but also a significant rise in net loss and ongoing 'going concern' doubts.

Verastem, Inc. reports Q2 2025 financial results, highlighting initial product revenue from its newly approved AVMAPKI FAKZYNJA CO-PACK and progress across its oncology pipeline.

Verastem Oncology announces first quarter 2025 financial results, highlighting the FDA approval and launch of AVMAPKI FAKZYNJA CO-PACK and progress in pipeline programs.

Verastem Oncology completed its rolling NDA submission for the avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer and is seeking accelerated approval.

Verastem Oncology announced positive second quarter results, highlighted by the initiation of a rolling NDA submission for their avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer.

Verastem Oncology announced its first quarter 2024 financial results and provided updates on its clinical programs, including plans for a rolling NDA submission for avutometinib and defactinib.

Verastem Oncology highlights FDA priority review for avutometinib plus defactinib in KRAS mutant recurrent LGSOC and advancements in other pipeline programs alongside its 2024 financial results.

Verastem Oncology reports significant advancements in its clinical programs, including the initiation of a Phase 3 trial for its lead drug combination and positive data readouts, alongside its full year 2023 financial results.

Verastem Inc. President and CEO Dan Paterson sold 20,871 shares of common stock to cover statutory withholding taxes upon the vesting of restricted stock units.

Verastem, Inc. CFO Daniel Calkins sold company stock to cover tax obligations related to vested restricted stock units.

Director Michael P. Bailey was granted 108,000 restricted stock units in Verastem, Inc. as part of an equity incentive plan.

Verastem, Inc. reports that Director Karin Tollefson acquired 36,000 shares of common stock through the vesting of RSUs on May 21, 2026.

Verastem, Inc. reports that Director Brian M. Stuglik was granted 36,000 Restricted Stock Units (RSUs) on May 21, 2026.

Verastem, Inc. reports that Director Eric K. Rowinsky was granted 36,000 Restricted Stock Units (RSUs) on May 21, 2026.

Verastem, Inc. will hold its 2025 Annual Meeting of Stockholders on May 22, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.

Verastem, Inc. will hold its annual stockholders meeting on May 23, 2024, to vote on director elections, an amended equity incentive plan, and other corporate matters.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Verastem Inc.'s common stock as of June 30, 2026.

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 7.0% of Verastem Inc.'s common stock as of June 30, 2026.

Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC report a beneficial ownership of 4.80% in Verastem, Inc.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5.23% in Verastem, Inc. common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 9,018,724 shares of Verastem, Inc. common stock, representing 9.9% of the class.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 1,360,391 shares of Verastem Inc. common stock, representing 1.55% of the class.